INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by INVO Bioscience, Inc. (INVO Fertility, Inc.) on September 26, 2016, reporting events that occurred on September 20, 2016. The company is a medical device firm focused on fertility solutions, specifically the INVOcell device and INVO Procedure.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors executed a significant leadership transition on September 20, 2016:
- Departures: Dr. Claude Ranoux was replaced as President, Treasurer, and Chief Scientist. He retains his position as a Director.
- Appointments: Kathleen Karloff was elected Chairman of the Board, President, and Chief Executive Officer (CEO). Robert Bowdring was elected Treasurer and Secretary.
- Compensation: No material plans, contracts, or awards were entered into or amended in connection with these elections.
Management Commentary and Risks
Management acknowledged Dr. Ranoux's 20-year contribution to the development of the INVOcell device, stating the company is on a path to help couples with fertility issues. The new leadership team brings extensive experience:
- Kathleen Karloff: Co-founder with over 30 years in medical device manufacturing, regulatory affairs, and FDA approvals. Previously served at Psivida Ltd and Boston Scientific.
- Robert Bowdring: Former CFO of the company (2008-2013) and current CFO at Dynasil Corporation. Holds a B.A. in Accounting.
The filing does not disclose specific risks, contingencies, or unusual items beyond the leadership transition.
Key Facts for Investor Verification
- Confirm the effective date of the leadership transition (September 20, 2016).
- Verify the continued role of Dr. Claude Ranoux as a Director despite his removal from executive roles.
- Review subsequent filings for any undisclosed compensation agreements or strategic shifts under the new CEO.
- Check the company's financial status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.